QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:ONCY

Oncolytics Biotech (ONCY) Price Target & Analyst Ratings

$2.19
+0.07 (+3.30%)
(As of 09/21/2023 ET)
Compare
Today's Range
$2.10
▼
$2.23
50-Day Range
$1.98
▼
$3.03
52-Week Range
$1.09
▼
$3.39
Volume
470,456 shs
Average Volume
562,892 shs
Market Capitalization
$158.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Oncolytics Biotech Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$7.67
250.08% Upside
High Prediction$15.00
Average Prediction$7.67
Low Prediction$3.00
TypeCurrent
9/21/22 to 9/21/23		1 Month Ago
8/22/22 to 8/22/23		3 Months Ago
6/23/22 to 6/23/23		1 Year Ago
9/21/21 to 9/21/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.67$7.67$4.00$6.00
Predicted Upside250.08% Upside362.79% Upside169.37% Upside227.87% Upside
Get Oncolytics Biotech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.


ONCY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ONCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Oncolytics Biotech Stock vs. The Competition

TypeOncolytics BiotechMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.65
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside250.08% Upside1,485.43% Upside696.90% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/16/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		P. Trucchio
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$15.00+650.00%
3/6/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy$6.00 ➝ $5.00+194.13%
3/6/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight
10/6/2022Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$3.00+136.22%
(Data available from 9/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ONCY Price Target - Frequently Asked Questions

What is Oncolytics Biotech's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Oncolytics Biotech stock is Buy based on the current 4 buy ratings for ONCY. The average twelve-month price prediction for Oncolytics Biotech is $7.67 with a high price target of $15.00 and a low price target of $3.00. Learn more on ONCY's analyst rating history.

Do Wall Street analysts like Oncolytics Biotech more than its competitors?

Analysts like Oncolytics Biotech more than other Medical companies. The consensus rating for Oncolytics Biotech is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how ONCY compares to other companies.

Does Oncolytics Biotech's stock price have much upside?

According to analysts, Oncolytics Biotech's stock has a predicted upside of 362.79% based on their 12-month price targets.

What analysts cover Oncolytics Biotech?

Oncolytics Biotech has been rated by HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ONCY) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -